Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
441 to 460 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation. | Emerg Microbes Infect | 2023 | 37144395 | PubTator, text mining | PubMed |
| SARS-CoV-2 Mpro Protease Variants of Concern Display Altered Viral Substrate and Cell Host Target Galectin-8 Processing but Retain Sensitivity toward Antivirals. | ACS Cent Sci | 2023 | 37122453 | PubTator, text mining | PubMed |
| MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference. | Sci Rep | 2023 | 37117213 | PubTator, text mining | PubMed |
| Discovery of Potential Inhibitors of SARS-CoV-2 Main Protease by a Transfer Learning Method. | Viruses | 2023 | 37112871 | PubTator, text mining | PubMed |
| Molecular Interaction of Nonsense-Mediated mRNA Decay with Viruses. | Viruses | 2023 | 37112798 | PubTator, text mining | PubMed |
| In Silico Analysis of SARS-CoV-2 Spike Proteins of Different Field Variants. | Vaccines (Basel) | 2023 | 37112648 | PubTator, text mining | PubMed |
| Design of Potent Inhibitors Targeting the Main Protease of SARS-CoV-2 Using QSAR Modeling, Molecular Docking, and Molecular Dynamics Simulations. | Pharmaceuticals (Basel) | 2023 | 37111365 | PubTator, text mining | PubMed |
| N-Acetyl Cysteine Restores the Diminished Activity of the Antioxidant Enzymatic System Caused by SARS-CoV-2 Infection: Preliminary Findings. | Pharmaceuticals (Basel) | 2023 | 37111348 | PubTator, text mining | PubMed |
| Phytochemicals of Withania somnifera as a Future Promising Drug against SARS-CoV-2: Pharmacological Role, Molecular Mechanism, Molecular Docking Evaluation, and Efficient Delivery. | Microorganisms | 2023 | 37110423 | PubTator, text mining | PubMed |
| Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease. | J Pers Med | 2023 | 37109050 | PubTator, text mining | PubMed |
| The Wheel of p53 Helps to Drive the Immune System. | Int J Mol Sci | 2023 | 37108808 | PubTator, text mining | PubMed |
| Phase-separated nucleocapsid protein of SARS-CoV-2 suppresses cGAS-DNA recognition by disrupting cGAS-G3BP1 complex. | Signal Transduct Target Ther | 2023 | 37100798 | PubTator, text mining | PubMed |
| Edible alginate-based films with anti-SARS-CoV-2 activity. | Food Microbiol | 2023 | 37098418 | PubTator, text mining | PubMed |
| In vitro evaluation of Lactiplantibacillus plantarum HOKKAIDO strain, effective lactic acid bacteria for calf diarrhea. | Front Vet Sci | 2023 | 37089407 | PubTator, text mining | PubMed |
| Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariants. | Antiviral Res | 2023 | 37086978 | PubTator, text mining | PubMed |
| Rapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6. | Nat Commun | 2023 | 37085489 | PubTator, text mining | PubMed |
| Non‑coding RNAs: Role of miRNAs and lncRNAs in the regulation of autophagy in hepatocellular carcinoma (Review). | Oncol Rep | 2023 | 37083063 | PubTator, text mining | PubMed |
| Genomic surveillance of SARS-CoV-2 strains circulating in Iran during six waves of the pandemic. | Influenza Other Respir Viruses | 2023 | 37078070 | PubTator, text mining | PubMed |
| Therapeutic strategies for COVID-19: progress and lessons learned. | Nat Rev Drug Discov | 2023 | 37076602 | PubTator, text mining | PubMed |
| Generation and Functional Analysis of Defective Viral Genomes during SARS-CoV-2 Infection. | mBio | 2023 | 37074178 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=23